Recent advances in managing/understanding the metabolic syndrome.

F1000Res 2019 3;8. Epub 2019 Apr 3.

Unidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14008, Mexico.

The metabolic syndrome (MetS) concept gathers in a single entity a set of metabolic abnormalities that have in common a close relationship with ectopic deposit of lipids, insulin resistance, and chronic low-grade inflammation. It is a valuable teaching tool to help health professionals to understand and integrate the consequences of lipotoxicity and the adverse metabolic consequences of insulin resistance. Also, it is useful to identify subjects with a high risk for having incident type 2 diabetes. Systems biology studies have gained a prominent role in understanding the interaction between adipose tissue dysfunction, insulin action, and the MetS traits and co-morbidities (that is, non-alcoholic steatohepatitis, or NASH). This approach may allow the identification of new therapeutic targets (that is, lipogenesis inhibitors for NASH). Treatment targets on MetS are the adoption of a healthy lifestyle, weight loss, and the control of the co-morbidities (hyperglycemia, dyslipidemia, arterial hypertension, among others). The long-term goals are the prevention of type 2 diabetes, cardiovascular events, and other MetS-related outcomes. In the last few decades, new drugs derived from the identification of innovative treatment targets have come on the market. These drugs have positive effects on more than one MetS component (that is, hyperglycemia and weight control). New potential treatment targets are under study.

Download full-text PDF

Source
https://f1000research.com/articles/8-370/v1
Publisher Site
http://dx.doi.org/10.12688/f1000research.17122.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449786PMC
April 2019
3 Reads

Publication Analysis

Top Keywords

treatment targets
12
type diabetes
8
metabolic syndrome
8
insulin resistance
8
approach allow
4
allow identification
4
identification therapeutic
4
nash approach
4
steatohepatitis nash
4
co-morbidities non-alcoholic
4
targets
4
non-alcoholic steatohepatitis
4
lipogenesis inhibitors
4
targets mets
4
mets adoption
4
nash treatment
4
inhibitors nash
4
targets lipogenesis
4
traits co-morbidities
4
therapeutic targets
4

References

(Supplied by CrossRef)
The Metabolic Syndrome: A Concept Hard to Define.
C Aguilar et al.
Arch Med Res. 2005
Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).
B Balkau et al.
Diabet Med. 1999

Similar Publications